2592 — Cloudbreak Pharma Share Price
Last trade - 00:00Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End null | Unit | null | null | null | null | null | nullE | nullE | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Cloudbreak Pharma Inc. is a clinical-stage ophthalmology biotechnology company dedicated to the development of various treatments. The Company is focusing on the in-house discovery, development and commercialization of ophthalmic therapies. The Company has two Core Products, CBT-001 and CBT-009, both of which are being proprietarily developed. Its Core Product, CBT-001, is indicated for the treatment of pterygium (a benign proliferative ocular surface disease), and it has commenced a Phase III multi-regional clinical trial (MRCT) in the United States and China. Its Core Product, CBT-009, is indicated for the treatment of juvenile myopia (myopia in children and adolescents aged 5 to 19) and has completed Phase I/II clinical trials. Its other drug candidates are in a relatively early development stage, including two other clinical-stage drug candidates, which are CBT-006 and CBT-004, and four pre-clinical-stage drug candidates, which are CBT-007, CBT-199, CBT-145, and CBT-011.
Directors
- Last Annual
- Last Interim
- Incorporated
- November 20th, 2020
- Public Since
- July 3rd, 2025
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Stock Exchange of Hong Kong Limited
- Address
- 8921 Research Drive, IRVINE, 92618
- Web
- https://cloudbreakpharma.com/
- Phone
- Auditors
Upcoming Events for 2592
Similar to 2592
Abbisko Cayman
Stock Exchange of Hong Kong Limited
Akeso
Stock Exchange of Hong Kong Limited
Alphamab Oncology
Stock Exchange of Hong Kong Limited
Antengene
Stock Exchange of Hong Kong Limited
Ascentage Pharma International
Stock Exchange of Hong Kong Limited
FAQ
As of Today at 19:58 UTC, shares in Cloudbreak Pharma are trading at HK$5.86. This share price information is delayed by 15 minutes.
Shares in Cloudbreak Pharma last closed at HK$5.86 and the price had moved by over the past 365 days. In terms of relative price strength the Cloudbreak Pharma share price has matched the FTSE Developed Asia Pacific Index by over the past year.
There is no consensus recommendation for this security.
Find out moreCloudbreak Pharma does not currently pay a dividend.
Cloudbreak Pharma does not currently pay a dividend.
Cloudbreak Pharma does not currently pay a dividend.
To buy shares in Cloudbreak Pharma you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of HK$5.86, shares in Cloudbreak Pharma had a market capitalisation of .
Here are the trading details for Cloudbreak Pharma:
- Country of listing: Hong Kong
- Exchange: HKG
- Ticker Symbol: 2592
Based on an overall assessment of its quality, value and momentum Cloudbreak Pharma is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cloudbreak Pharma. Over the past six months, its share price has matched the FTSE Developed Asia Pacific Index by .
As of the last closing price of HK$5.86, shares in Cloudbreak Pharma were trading matched their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Cloudbreak Pharma PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at HK$5.86.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Cloudbreak Pharma's directors